Splanchnic and systemic vasodilation: The experimental models

Journal of Clinical Gastroenterology

Volumn 41, Issue SUPPL. 3, 2007, Pages

  Wiest, Reiner ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Arterial vasodilation; Nitric oxide; Portal hypertension; Smooth muscle contraction

Indexed keywords

ADRENOMEDULLIN; CALCITONIN GENE RELATED PEPTIDE; CARBON MONOXIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; ENDOTHELIUM DERIVED RELAXING FACTOR; GLUCAGON; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OCTREOTIDE; SOMATOSTATIN; SUBSTANCE P; VASOACTIVE INTESTINAL POLYPEPTIDE; VASODILATOR AGENT;

CONFERENCE PAPER; CORRELATION ANALYSIS; EXPERIMENTAL MODEL; HEMODYNAMICS; MOLECULAR DYNAMICS; NONHUMAN; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTION; SPLANCHNIC BLOOD FLOW; SYSTEMIC CIRCULATION; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION;

ANIMALS; ARTERIES; BIOLOGICAL FACTORS; CARBON MONOXIDE; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION, PORTAL; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; RESEARCH DESIGN; SIGNAL TRANSDUCTION; SPLANCHNIC CIRCULATION; TIME FACTORS; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 35848929239     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318157cb57     Document Type: Conference Paper

References (174)

1. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences (editorial; comment). (Review) (64 refs). Hepatology. 1994;20:1359-1363.
2. Groszmann RJ, Abraldes JG. Portal hypertension: from bedside to bench. J Clin Gastroenterol. 2005;39(4 suppl 2):S125-S130.
3. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006;43(2 suppl 1):S121-S131.
4. Lieberman FL, Ito S, Reynolds TB. Effective plasma volume in cirrhosis with ascites. Evidence that a decreased value does not account for renal sodium retention, a spontaneous reduction in glomerular filtration rate (GFR), and a fall in GFR during druginduced diuresis. J Clin Invest. 1969;48:975-981.
5. Guyton AC, Lindsey AW, Kaufmann B. Effect of mean circulatory filling pressure and other peripheral circulatory factors on cardiac output. Am J Physiol. 1955;180:463-468.
6. Sikuler E, Groszmann RJ. Interaction of flow and resistance in maintenance of portal hypertension in a rat model. Am J Physiol. 1986;250:G205-G212.
7. Palma DT, Fallon MB. The hepatopulmonary syndrome. J Hepatol. 2006;45:617-625.
8. Lockwood AH, Yap EW, Rhoades HM, et al. Altered cerebral blood flow and glucose metabolism in patients with liver disease and minimal encephalopathy. J Cereb Blood Flow Metab. 1991;11:331-336.
9. Aggarwal S, Kramer D, Yonas H, et al. Cerebral hemodynamic and metabolic changes in fulminant hepatic failure: a retrospective study. Hepatology. 1994;19:80-87.
10. Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol. 1983;244:G52-G57.
11. Vorobioff J, Bredfeldt JE, Groszmann RJ. Increased blood flow through the portal system in cirrhotic rats. Gastroenterology. 1984;87:1120-1126.
12. Abraldes JG, Pasarin M, Garcia-Pagan JC. Animal models of portal hypertension. World J Gastroenterol. 2006;12:6577-6584.
13. Chojkier M, Groszmann RJ. Measurement of portal-systemic shunting in the rat by using gamma-labeled microspheres. Am J Physiol. 1981;240:G371-G375.
14. Groszmann RJ, Vorobioff J, Riley E. Splanchnic hemodynamics in portal-hypertensive rats: measurement with gamma-labeled microspheres. Am J Physiol. 1982;242:G156-G160.
15. Colombato LA, Albillos A, Groszmann RJ. Temporal relationship of peripheral vasodilatation, plasma volume expansion and the hyperdynamic circulatory state in portal-hypertensive rats. Hepatology. 1992;15:323-328.
16. Sikuler E, Kravetz D, Groszmann RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Physiol. 1985;248:G618-G625.
17. Abraldes JG, Iwakiri Y, Loureiro-Silva M, et al. Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. Am J Physiol Gastrointest Liver Physiol. 2006;290:G980-G987.
18. Tsai MH, Iwakiri Y, Cadelina G, et al. Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats. Gastroenterology. 2003;125:1452-1461.
19. Sarin SK, Groszmann RJ, Mosca PG, et al. Propranolol ameliorates the development of portal-systemic shunting in a chronic murine schistosomiasis model of portal hypertension. J Clin Invest. 1991;87:1032-1036.
20. Sarin SK, Mosca P, Sabba C, et al. Hyperdynamic circulation in a chronic murine schistosomiasis model of portal hypertension. Hepatology. 1991;13:581-584.
21. Morgan JS, Groszmann RJ, Rojkind M, et al. Hemodynamic mechanisms of emerging portal hypertension caused by schistosomiasis in the hamster. Hepatology. 1990;11:98-104.
22. Bosch J, Enriquez R, Groszmann RJ, et al. Chronic bile duct ligation in the dog: hemodynamic characterization of a portal hypertensive model. Hepatology. 1983;3:1002-1007.
23. Li X, Benjamin IS, Alexander B. Reproducible production of thioacetamide-induced macronodular cirrhosis in the rat with no mortality. J Hepatol. 2002;36:488-493.
24. Chang SW, Ohara N. Pulmonary circulatory dysfunction in rats with biliary cirrhosis. An animal model of the hepatopulmonary syndrome. Am Rev Respir Dis. 1992;145(4 Pt 1):798-805.
25. Proctor E, Chatamra K. High yield micronodular cirrhosis in the rat. Gastroenterology. 1982;83:1183-1190.
26. Laleman W, Vander EI, Zeegers M, et al. A stable model of cirrhotic portal hypertension in the rat: thioacetamide revisited. Eur J Clin Invest. 2006;36:242-249.
27. Iwakiri Y, Tsai MH, McCabe TJ, et al. Phosphorylation of eNOS initiates excessive NO production in early phases of portal hypertension. Am J Physiol Heart Circ Physiol. 2002;282:H2084-H2090.
28. Lee FY, Colombato LA, Albillos A, et al. N omega-nitro-L-arginine administration corrects peripheral vasodilation and systemic capillary hypotension and ameliorates plasma volume expansion and sodium retention in portal hypertensive rats. Hepatology. 1993;17:84-90.
29. Iwakiri Y, Cadelina G, Sessa WC, et al. Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension. Am J Physiol Gastrointest Liver Physiol. 2002;283:G1074-G1081.
30. Buckberg GD, Luck JC, Payne DB, et al. Some sources of error in measuring regional blood flow with radioactive microspheres. J Appl Physiol. 1971;31:598-604.
31. Dole WP, Jackson DL, Rosenblatt JI, et al. Relative error and variability in blood flow measurements with radiolabeled microspheres. Am J Physiol. 1982;243:H371-H378.
32. Sakurabayashi S, Koh KC, Chen L, et al. Octreotide ameliorates the increase in collateral blood flow during postprandial hyperemia in portal hypertensive rats. J Hepatol. 2002;36:507-512.
33. Cowan RE, Jackson BT, Grainger SL, et al. Effects of anesthetic agents and abdominal surgery on liver blood flow. Hepatology. 1991;14:1161-1166.
34. Belghiti J, Blanchet L, Lebrec D. Effects of general anaesthesia on portal venous pressure in the rat. Eur Surg Res. 1981;13:285-289.
35. McGregor DD. The effect of sympathetic nerve stimulation on vasoconstrictor responses in perfused mesenteric vessels of the rat. J Physiol (London). 1965;177:21-30.
36. Benoit JN, Barrowman JA, Harper SL, et al. Role of humoral factors in the intestinal hyperemia associated with chronic portal hypertension. Am J Physiol. 1984;247:G486-G493.
37. Korthuis RJ, Benoit JN, Kvietys PR, et al. Humoral factors may mediate increased rat hindquarter blood flow in portal hypertension. Am J Physiol. 1985;249:H827-H833.
38. Sikuler E, Groszmann RJ. Hemodynamic studies in a parabiotic model of portal hypertension. Experientia. 1985;41:1323-1324.
39. Sherwin R. Hyperglucagonemia in Laennec's cirrhosis: the role of portal-systemic shunting. New Engl J Med. 1974;290:239-242.
40. Sikuler E, Groszmann RJ. Hemodynamic studies in long- and short-term portal hypertensive rats: the relation to systemic glucagon levels. Hepatology. 1986;6:414-418.
41. Benoit JN, Zimmerman B, Premen AJ, et al. Role of glucagon in splanchnic hyperemia of chronic portal hypertension. Am J Physiol. 1986;251:G674-G677.
42. Albillos A, Colombato LA, Lee FY, et al. Octreotide ameliorates vasodilatation and Na+ retention in portal hypertensive rats. Gastroenterology. 1993;104:575-579.
43. Pizcueta MP, Garcia-Pagan JC, Fernandez M, et al. Glucagon hinders the effects of somatostatin on portal hypertension. A study in rats with partial portal vein ligation. Gastroenterology. 1991;101:1710-1715.
44. Das S, Chen L, Sakurabayashi S, et al. The effect of different somatostatin-receptor (SSTR) subtype specific analogs on pre- and post-prandial superior mesenteric artery blood flow in portal hypertensive rats. Hepatology. 1998;28:447A.
45. Guevara M, Gines P, Jimenez W, et al. Increased adrenomedullin levels in cirrhosis: relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology. 1998;114:336-343.
46. Nuki C, Kawasaki H, Kitamura K, et al. Vasodilator effect of adrenomedullin and calcitonin gene-related peptide receptors in rat mesenteric vascular beds. Biochem Biophys Res Commun. 1993;196:245-251.
47. Nishimatsu H, Suzuki E, Nagata D, et al. Adrenomedullin induces endothelium-dependent vasorelaxation via the phosphatidylinositol 3-kinase/Akt-dependent pathway in rat aorta. Circ Res. 2001;89:63-70.
48. Warner L, Skorecki K, Blendis LM, et al. Atrial natriuretic factor and liver disease. Hepatology. 1993;17:500-513.
49. Genecin P, Polio J, Colombato LA, et al. Bile acids do not mediate the hyperdynamic circulation in portal hypertensive rats. Am J Physiol. 1990;259:G21-G25.
50. Groszmann RJ, de Franchis R. Portal hypertension. In: Schiff E, Madrey W, Sorel JB, eds. Diseases of the Liver. 8th ed. 1999.
51. Sessa WC. The nitric oxide synthase family of proteins. (Review) (141 refs). J Vasc Res. 1994;31:131-143.
52. Takahashi M, Ishida T, Traub O, et al. Mechanotransduction in endothelial cells: temporal signaling events in response to shear stress (Review) (55 refs). J Vasc Res. 1997;34:212-219.
53. Ignacio CS, Curling PE, Childres WF, et al. Nitric oxide-synthesizing perivascular nerves in the rat middle cerebral artery. Am J Physiol. 1997;273(2 Pt 2):R661-R668.
54. Toda N, Ayajiki K, Uchiyama M, et al. Nitric oxide-mediated neurogenic vasodilatation in isolated monkey lingual arteries. Am J Physiol. 1997;272(4 Pt 2):H1582-H1588.
55. Toda N, Okamura T. Regulation of arterial tone by nitroxidergic nerves. News in Physiol Sci. 1991;7:148-152.
56. Claria J, Jimenez W, Ros J, et al. Pathogenesis of arterial hypotension in cirrhotic rats with ascites: role of endogenous nitric oxide. Hepatology. 1992;15:343-349.
57. Lee FY, Albillos A, Colombato LA, et al. The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal hypertensive rats. Hepatology. 1992;16:1043-1048.
58. Pizcueta P, Pique JM, Fernandez M, et al. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology. 1992;103:1909-1915.
59. Pizcueta MP, Pique JM, Bosch J, et al. Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension. Br J Pharmacol. 1992;105:184-190.
60. Lee FY, Colombato LA, Albillos A, et al. Administration of N omega-nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology. 1993;105:1464-1470.
61. Casadevall M, Pique JM, Cirera I, et al. Increased blood hemoglobin attenuates splanchnic vasodilation in portal-hypertensive rats by nitric oxide inactivation. Gastroenterology. 1996;110:1156-1165.
62. Niederberger M, Martin PY, Gines P, et al. Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats. Gastroenterology. 1995;109:1624-1630.
63. Theodorakis NG, Wang YN, Skill NJ, et al. The role of nitric oxide synthase isoforms in extrahepatic portal hypertension: studies in gene-knockout mice. Gastroenterology. 2003;124:1500-1508.
64. Hartleb M, Moreau R, Cailmail S, et al. Vascular hyporesponsiveness to endothelin 1 in rats with cirrhosis (see comments). Gastroenterology. 1994;107:1085-1093.
65. Kiel JW, Pitts V, Benoit JN, et al. Reduced vascular sensitivity to norepinephrine in portal-hypertensive rats. Am J Physiol. 1985;248:G192-G195.
66. Sieber CC, Groszmann RJ. In vitro hyporeactivity to methoxamine in portal hypertensive rats: reversal by nitric oxide blockade. Am J Physiol. 1992;262:G996-1001.
67. Sieber CC, Groszmann RJ. Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats. Gastroenterology. 1992;103:235-239.
68. Braillon A, Cailmail S, Gaudin C, et al. Reduced splanchnic vasoconstriction to angiotensin II in conscious rats with biliary cirrhosis. J Hepatol. 1993;17:86-90.
69. Castro A, Jimenez W, Claria J, et al. Impaired responsiveness to angiotensin II in experimental cirrhosis: role of nitric oxide (see comments). Hepatology. 1993;18:367-372.
70. Sieber CC, Lopez-Talavera JC, Groszmann RJ. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. Gastroenterology. 1993;104:1750-1754.
71. Sieber CC, Sumanovski LT, Moll-Kaufmann C, et al. Hyposensitivity to nerve stimulation in portal hypertensive rats: role of nitric oxide. Eur J Clin Invest. 1997;27:902-907.
72. Atucha NM, Shah V, Garcia-Cardena G, et al. Role of endothelium in the abnormal response of mesenteric vessels in rats with portal hypertension and liver cirrhosis. Gastroenterology. 1996;111:1627-1632.
73. Hori N, Wiest R, Groszmann RJ. Enhanced release of nitric oxide in response to changes in flow and shear stress in the superior mesenteric arteries of portal hypertensive rats. Hepatology. 1998;28:1467-1473.
74. Wiest R, Hori N, Cadelina G, et al. Increased nitric oxide release in response to vasoconstrictors in the superior mesenteric arterial bed of cirrhotic rats. Hepatology. 1997;26:A390.
75. Hori N, Groszmann RJ. Direct evidence for increased functional activity of eNOS in superior mesenteric arterial beds of portal hypertensive rats. Hepatology. 1996;24:A749.
76. Martin PY, Xu DL, Niederberger M, et al. Upregulation of endothelial constitutive NOS: a major role in the increased NO production in cirrhotic rats. Am J Physiol. 1996;270:F494-F499.
77. Martin PY, Ohara M, Gines P, et al. Nitric oxide synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites. J Clin Invest. 1998;101:235-242.
78. Niederberger M, Gines P, Martin PY, et al. Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats. Hepatology. 1996;24:947-951.
79. Wiest R, Das S, Cadelina G, et al. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest. 1999;104:1223-1233.
80. Claria J, Jimenez W, Ros J, et al. Increased nitric oxide-dependent vasorelaxation in aortic rings of cirrhotic rats with ascites (see comments). Hepatology. 1994;20:1615-1621.
81. Heinemann A, Stauber RE. Vasodilator responses to nitric oxide are enhanced in mesenteric arteries of portal hypertensive rats. Eur J Clin Invest. 1996;26:824-826.
82. Jurzik L, Froh M, Straub RH, et al. Up-regulation of nNOS and associated increase in nitrergic vasodilation in superior mesenteric arteries in pre-hepatic portal hypertension. J Hepatol. 2005;43:258-265.
83. Moll-Kaufmann C, Sumanovski LT, Sieber CC. Neurally mediated vasodilatation in normal and portal hypertensive rats: role of nitric oxide and calcitonin gene-related peptide. J Hepatol. 1998;28:1031-1036.
84. Kwon SY, Groszmann RJ, Iwakiri Y. Increased neuronal nitric oxide synthase interaction with soluble guanylate cyclase contributes to the splanchnic arterial vasodilation in portal hypertensive rats. Hepatol Res. 2007;37:58-67.
85. Fernandez M, Garcia-Pagan JC, Casadevall M, et al. Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal-hypertensive rats. Gastroenterology. 1995;108:1487-1495.
86. Battista S, Bar F, Mengozzo G, et al. Hyperdynamic circulation in patients with cirrhosis: direct measurement of nitric oxide levels in hepatic and portal veins. J Hepatol. 1997;26:75-80.
87. Bernardi M, Trevisani F. Systemic and regional hemodynamics in pre-ascitic cirrhosis [editorial; comment]. J Hepatol. 1997;27:588-591.
88. Fernandez-Seara J, Prieto J, Quiroga J, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology. 1989;97:1304-1312.
89. Ortiz MC, Fortepiani LA, Martinez C, et al. Vascular hyporesponsiveness in aortic rings from cirrhotic rats: role of nitric oxide and endothelium. Clin Sci (Colch). 1996;91:733-738.
90. Weigert AL, Martin PY, Niederberger M, et al. Endotheliumdependent vascular hyporesponsiveness without detection of nitric oxide synthase induction in aortas of cirrhotic rats. Hepatology. 1995;22:1856-1862.
91. Gadano AC, Sogni P, Yang S, et al. Endothelial calciumcalmodulin dependent nitric oxide synthase in the in vitro vascular hyporeactivity of portal hypertensive rats. J Hepatol. 1997;26:678-686.
92. Xu L, Carter EP, Ohara M, et al. Neuronal nitric oxide synthase and systemic vasodilation in rats with cirrhosis. Am J Physiol. 2000;279:F1110-F1115.
93. Fallon MB, Abrams GA, Luo B, et al. The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome. Gastroenterology. 1997;113:606-614.
94. Ling Y, Zhang J, Luo B, et al. The role of endothelin-1 and the endothelin B receptor in the pathogenesis of hepatopulmonary syndrome in the rat. Hepatology. 2004;39:1593-1602.
95. Nunes H, Lebrec D, Mazmanian M, et al. Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. Am J Respir Crit Care Med. 2001;164:879-885.
96. Niederberger M, Gines P, Tsai P, et al. Increased aortic cyclic guanosine monophosphate concentration in experimental cirrhosis in rats: evidence for a role of nitric oxide in the pathogenesis of arterial vasodilation in cirrhosis. Hepatology. 1995;21:1625-1631.
97. Wiest R, Shah V, Sessa WC, et al. NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol. 1999;276(4 Pt 1):G1043-G1051.
98. Garcia-Cardena G, Fan R, Shah V, et al. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature. 1998;392:821-824.
99. Shah V, Wiest R, Garcia-Cardena G, et al. HSP 90 regulation of endothelial nitric oxide synthase contributes to vascular control in portal hypertension. Am J Physiol. 1999;277:G463-G468.
100. Fleming I, Busse R. Signal transduction of eNOS activity. Cardiovasc Res. 1999;43:532-541.
101. Tsai MH, Iwakiri Y, Cadelina G, et al. Mesenteric vasoconstriction triggers eNOS. Gastroenterology. 2004.
102. Papapetropoulos A, Garcia-Cardena G, Madri JA, et al. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest. 1997;100:3131-3139.
103. Bhagat K, Hingorani AD, Palacios M, et al. Cytokine-induced venodilatation in humans in vivo: eNOS masquerading as iNOS. Cardiovasc Res. 1999;41:754-764.
104. Lopez-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology. 1995;108:761-767.
105. Lopez-Talavera JC, Cadelina G, Olchowski J, et al. Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology. 1996;23:1616-1621.
106. Garcia-Tsao G, Albillos A, Barden GE, et al. Bacterial translocation in acute and chronic portal hypertension (see comments). Hepatology. 1993;17:1081-1085.
107. Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology. 1993;18:1139-1143.
108. Werner ER, Werner-Felmayer G, Wachter H. Tetrahydrobiopterin and cytokines. [Review] (132 refs). Proc Soc Exp Biol Med. 1993;203:1-12.
109. Werner-Felmayer G, Werner ER, Fuchs D, et al. Pteridine biosynthesis in human endothelial cells. Impact on nitric oxidemediated formation of cyclic GMP. J Biol Chem. 1993;268:1842-1846.
110. Rosenkranz-Weiss P, Sessa WC, Milstien S, et al. Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells. Elevations in tetrahydrobiopterin levels enhance endothelial nitric oxide synthase specific activity (see comments). J Clin Invest. 1994;93:2236-2243.
111. Katusic ZS, Stelter A, Milstien S. Cytokines stimulate GTP cyclohydrolase I gene expression in cultured human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol. 1998;18:27-32.
112. Wever RMF, van Dam T, van Rijn HJM, et al. Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase. Biochem Biophys Res Commun. 1997;237:340-344.
113. Stroess E, Kastelein J, Cosentino F, et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest. 1997;99:41-46.
114. Wiest R, Tsai MH, Garcia-Tsao G, et al. Bacterial translocation up-regulates GTP-cyclohydrolase I in mesenteric vasculature of cirrhotic rats. Hepatology. 2003;38:1508-1515.
115. Tazi KA, Moreau R, Herve P, et al. Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: role of Akt signaling. Gastroenterology. 2005;129:303-314.
116. Batkai S, Jarai Z, Wagner JA, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med. 2001;7:827-832.
117. Domenicalli M, Ros J, Fernandez-Varo G, et al. Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors. Gut. 2005;54:522-527.
118. Fernandez-Rodriguez CM, Romero J, Petros TJ, et al. Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis. Liver Int. 2004;24:477-483.
119. Fernandez-Rodriguez CM, Prieto J, Quiroga J, et al. Plasma levels of substance P in liver cirrhosis: relationship to the activation of vasopressor systems and urinary sodium excretion. Hepatology. 1995;21:35-40.
120. John Judy St. PM, Ding-Li Xu. Effect of circulating substances known to be increased in cirrhosis on endothelial nitric oxide synthase (eNOS) mRNA. J Am Soc Nephrol. 1996;7:A1619.
121. Genesca J, Gonzalez A, Catalan R, et al. Adrenomedullin, a vasodilator peptide implicated in hemodynamic alterations of liver cirrhosis: relationship to nitric oxide. Dig Dis Sci. 1999;44:372-376.
122. Laleman W, Omasta A, van De CM, et al. A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis. Hepatology. 2005;42:1382-1390.
123. Lluch P, Torondel B, Medina P, et al. Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. J Hepatol. 2004;41:55-59.
124. Brandes RP, Schmitz-Winnenthal FH, Feletou M, et al. An endothelium-derived hyperpolarizing factor distinct from NO and prostacyclin is a major endothelium-dependent vasodilator in resistance vessels of wild-type and endothelial NO synthase knockout mice. Proc Natl Acad Sci USA. 2000;97:9747-9752.
125. Scotland RS, Chauhan S, Vallance PJ, et al. An endothelium-derived hyperpolarizing factor-like factor moderates myogenic constriction of mesenteric resistance arteries in the absence of endothelial nitric oxide synthase-derived nitric oxide. Hypertension. 2001;38:833-839.
126. Barriere E, Tazi KA, Rona JP, et al. Evidence for an endothelium-derived hyperpolarizing factor in the superior mesenteric artery from rats with cirrhosis. Hepatology. 2000;32:935-941.
127. Atucha NM, Ortiz MC, Fortepiani LA, et al. Role of cGMP and K-channels as mediators of the mesenteric vascular hyporesponsiveness in portal hypertensive rats. Hepatology. 1998;27:900-905.
128. Bauersachs J, Popp R, Fleming I, et al. Nitric oxide and endothelium-derived hyperpolarizing factor: formation and interactions. Prostaglandins Leukot Essent Fatty Acids. 1997;57:439-446.
129. Bauersachs J, Popp R, Hecker M, et al. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation. 1996;94:3341-3347.
130. Sun D, Huang A, Smith CJ, et al. Enhanced release of prostaglandins contributes to flow-induced arteriolar dilation in eNOS knockout mice. Circ Res. 1999;85:288-293.
131. Hou MC, Cahill PA, Zhang S, et al. Enhanced cyclooxygenase-1 expression within the superior mesenteric artery of portal hypertensive rats: role in the hyperdynamic circulation. Hepatology. 1998;27:20-27.
132. Sitzmann JV, Campbell K, Wu Y, et al. Prostacyclin production in acute, chronic, and long-term experimental portal hypertension. Surgery. 1994;115:290-294.
133. Potenza MA, Botrugno OA, De Salvia MA, et al. Endothelial COX-1 and -2 differentially affect reactivity of MVB in portal hypertensive rats. Am J Physiol Gastrointest Liver Physiol. 2002;283:G587-G594.
134. Jeremy JY, Mikhailidis DP, Karatapanis S, et al. Altered prostacyclin synthesis by aortae from hepatic portal vein-constricted rats: evidence for effects on protein kinase C and calcium. J Hepatol. 1994;21:1017-1022.
135. Chen YC, Gines P, Yang J, et al. Increased vascular heme oxygenase-1 expression contributes to arterial vasodilation in experimental cirrhosis in rats. Hepatology. 2004;39:1075-1087.
136. Bolognesi M, Sacerdoti D, Di Pascoli M, et al. Haeme oxygenase mediates hyporeactivity to phenylephrine in the mesenteric vessels of cirrhotic rats with ascites. Gut. 2005;54:1630-1636.
137. Sacerdoti D, Abraham NG, Oyekan AO, et al. Role of the heme oxygenases in abnormalities of the mesenteric circulation in cirrhotic rats. J Pharmacol Exp Ther. 2004;308:636-643.
138. Erario MA, Gonzales S, Romay S, et al. Role of heme oxygenase/carbon monoxide pathway on the vascular response to noradrenaline in portal hypertensive rats. Clin Exp Pharmacol Physiol. 2005;32:196-201.
139. Maines MD, Trakshel GM, Kutty RK. Characterization of two constitutive forms of rat liver microsomal heme oxygenase. Only one molecular species of the enzyme is inducible. J Biol Chem. 1986;261:411-419.
140. Zhang J, Ling Y, Luo B, et al. Analysis of pulmonary heme oxygenase-1 and nitric oxide synthase alterations in experimental hepatopulmonary syndrome. Gastroenterology. 2003;125:1441-1451.
141. Lin HC, Yang YY, Huang YT, et al. Vascular contractile response and signal transduction in endothelium-denuded aorta from cirrhotic rats. World J Gastroenterol. 2005;11:2306-2312.
142. Heller J, Schepke M, Gehnen N, et al. Altered adrenergic responsiveness of endothelium-denuded hepatic arteries and portal veins in patients with cirrhosis. Gastroenterology. 1999;116:387-393.
143. Murray BM, Paller MS. Decreased pressor reactivity to angiotensin II in cirrhotic rats. Evidence for a post-receptor defect in angiotensin action. Circ Res. 1985;57:424-431.
144. Neef M, Biecker E, Heller J, et al. Portal hypertension is associated with increased mRNA levels of vasopressor G-protein-coupled receptors in human hepatic arteries. Eur J Clin Invest. 2003;33:249-255.
145. Hennenberg M, Trebicka J, Biecker E, et al. Vascular dysfunction in human and rat cirrhosis: role of receptor-desensitizing and calcium-sensitizing proteins. Hepatology. 2007;45:495-506.
146. Ehrlich BE, Kaftan E, Bezprozvannaya S, et al. The pharmacology of intracellular Ca(2+)-release channels [Review] [50 refs]. Trends Pharmacol Sci. 1994;15:145-149.
147. Van Breemen C, Cauvin C, Yamamoto H, et al. Vascular smooth muscle calcium channels [Review] (26 refs). J Cardiovasc Pharmacol. 1987;10(suppl 10):S10-S16.
148. Piascik MT, Soltis EE, Piascik MM, et al. Alpha-adrenoceptors and vascular regulation: molecular, pharmacologic and clinical correlates [Review] (303 refs). Pharmacol Ther. 1996;72:215-241.
149. Lee MW, Severson DL. Signal transduction in vascular smooth muscle: diacylglycerol second messengers and PKC action [Review] (188 refs). Am J Physiol. 1994;267(3 Pt 1):C659-C678.
150. Trombino C, Tazi KA, Gadano A, et al. Protein kinase C alterations in aortic vascular smooth muscle cells from rats with cirrhosis. J Hepatol. 1998;28:670-676.
151. Tazi KA, Moreau R, Heller J, et al. Changes in protein kinase C isoforms in association with vascular hyporeactivity in cirrhotic rat aortas. Gastroenterology. 2000;119:201-210.
152. Hennenberg M, Biecker E, Trebicka J, et al. Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology. 2006;130:838-854.
153. Benarroch EE. Neuropeptides in the sympathetic system: presence, plasticity, modulation, and implications. Ann Neurol. 1994;36:6-13.
154. Selbie LA, Hill S. G protein-coupled receptor cross-talk: the finetuning of multiple receptor-signalling pathways. Trends Pharmacol Sci. 1998;19:93.
155. Toernebrandt K, Nobin A, Owman C. Pharmacological characterization of alpha-adrenergic receptor subtypes mediating contraction in human mesenteric arteries and veins. Blood Vessels. 1985;22:179-195.
156. Joh T, Granger DN, Benoit JN. Endogenous vasoconstrictor tone in intestine of normal and portal hypertensive rats. Am J Physiol. 1993;264:H171-H177.
157. Pernow J. Co-release and functional interactions of neuropeptide Y and noradrenaline in peripheral sympathetic vascular control. Acta Physiol Scand Suppl. 1988;568:1-56.
158. Uddman R, Moller S, Nilsson T, et al. Neuropeptide Y Y1 and neuropeptide Y Y2 receptors in human cardiovascular tissues. Peptides. 2002;23:927-934.
159. Wahlestedt C, Edvinsson L, Ekblad E, et al. Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: mode of action. J Pharmacol Exp Ther. 1985;234:735-741.
160. Wahlestedt C, Yanaihara N, Hakanson R. Evidence for different pre-and post-junctional receptors for neuropeptide Y and related peptides. Regul Pept. 1986;13:307-318.
161. Wahlestedt C, Hakanson R, Vaz CA, et al. Norepinephrine and neuropeptide Y: vasoconstrictor cooperation in vivo and in vitro. Am J Physiol. 1990;258(3 Pt 2):R736-R742.
162. Han S, Yang CL, Chen X, et al. Direct evidence for the role of neuropeptide Y in sympathetic nerve stimulation-induced vasoconstriction. Am J Physiol. 1998;274(1 Pt 2):H290-H294.
163. Racchi H, Schliem AJ, Donoso MV, et al. Neuropeptide Y Y1 receptors are involved in the vasoconstriction caused by human sympathetic nerve stimulation. Eur J Pharmacol. 1997;329:79-83.
164. Linder L, Lautenschlager BM, Haefeli WE. Subconstrictor doses of neuropeptide Y potentiate alpha 1-adrenergic venoconstriction in vivo. Hypertension. 1996;28:483-487.
165. Westfall TC, Carpentier S, Chen X, et al. Prejunctional and postjunctional effects of neuropeptide Y at the noradrenergic neuroeffector junction of the perfused mesenteric arterial bed of the rat. J Cardiovasc Pharmacol. 1987;10:716-722.
166. Westfall TC, Chen XL, Ciarleglio A, et al. In vitro effects of neuropeptide Y at the vascular neuroeffector junction. Ann N Y Acad Sci. 1990;611:145-155.
167. Zukowska-Grojec Z, Haass M, Bayorh MA. Neuropeptide Y and peptide YY mediate nonadrenergic vasoconstriction and modulate sympathetic responses in rats. Regul Pept. 1986;15:99-110.
168. Zukowska-Grojec Z. Neuropeptide Y. A novel sympathetic stress hormone and more. Ann N Y Acad Sci. 1995;771:219-233.
169. Zukowska-Grojec Z. Neuropeptide Y: an adrenergic cotransmitter, vasoconstrictor, and a nerve-derived vascular growth factor. Adv Pharmacol. 1998;42:125-128.
170. Aubert JF, Waeber B, Rossier B, et al. Effects of neuropeptide Y on the blood pressure response to various vasoconstrictor agents. J Pharmacol Exp Ther. 1988;246:1088-1092.
171. Cressier F, Criscione L, Hofbauer KG. Mechanism of interaction between neuropeptide Y and angiotensin II in the rabbit femoral artery. Eur J Pharmacol. 1995;272:57-65.
172. Wiest R, Jurzik L, Moleda L, et al. Enhanced Y1-receptor-mediated vasoconstrictive action of neuropeptide Y (NPY) in superior mesenteric arteries in portal hypertension. J Hepatol. 2006;44:512-519.
173. Wiest R, Tsai MH, Groszmann RJ. Octreotide potentiates PKCdependent vasoconstrictors in portal-hypertensive and control rats. Gastroenterology. 2001;120:975-983.
174. Chatila R, Gupta TK, Ferayorni L, et al. Local arterial vasoconstriction induced by octreotide in patients with cirrhosis. Hepatol. 1998;28:A130.